Intergeneric poliovirus recombinants for the treatment of malignant glioma.

Published

Journal Article

Poliovirus neuropathogenicity depends on sequences within the 5' nontranslated region of the virus. Exchange of the poliovirus internal ribosomal entry site with its counterpart from human rhinovirus type 2 resulted in attenuation of neurovirulence in primates. Despite deficient virus propagation in cells of neuronal origin, nonpathogenic polio recombinants retain excellent growth characteristics in cell lines derived from glial neoplasms. Susceptibility of malignant glioma cells to poliovirus may be mediated by expression of a poliovirus receptor, CD155, in glial neoplasms. Intergeneric polio recombinants with heterologous internal ribosomal entry site elements unfolded strong oncolytic potential against experimentally induced gliomas in athymic mice. Our observations suggest that highly attenuated poliovirus recombinants may have applicability as biotherapeutic antineoplastic agents.

Full Text

Duke Authors

Cited Authors

  • Gromeier, M; Lachmann, S; Rosenfeld, MR; Gutin, PH; Wimmer, E

Published Date

  • June 2000

Published In

Volume / Issue

  • 97 / 12

Start / End Page

  • 6803 - 6808

PubMed ID

  • 10841575

Pubmed Central ID

  • 10841575

Electronic International Standard Serial Number (EISSN)

  • 1091-6490

International Standard Serial Number (ISSN)

  • 0027-8424

Digital Object Identifier (DOI)

  • 10.1073/pnas.97.12.6803

Language

  • eng